Monday, September 14, 2020

High price blocks access to PrEP drugs

 High price blocks access to PrEP drugs

Prices of preexposure prophylaxis drugs to prevent HIV rose an average of 5% annually between 2014 and 2018, putting the drugs out of reach even for some people with insurance, researchers reported in the Annals of Internal Medicine. Insurers cover about 94% of PrEP costs, but many consumers still struggle with out-of-pocket costs because list prices are so high, says study author Nathan Furukawa.

Full Story: HealthDay News (9/10) 

No comments:

Post a Comment